Tamiflu (Oseltamivir Phosphate) Market
                     OTC Distribution Drives Tamiflu (Oseltamivir Phosphate) Market
High prevalence of influenza and flu has created a demand for Tamiflu 
(Oseltamivir Phosphate). Thus, companies are entering into strategic 
deals to gain rights for over-the-counter (OTC) distribution of the 
medication. For instance, in July 2019, leading French multinational 
pharmaceutical company Sanofi entered into an agreement with Roche-a 
Swiss multinational healthcare company, to gain rights for over-the-
counter distribution of Tamiflu in the U.S. Such deals are boosting the 
growth of the Tamiflu (Oseltamivir Phosphate) market, which is projected 
to reach a revenue of ~US$ 940 Mn by the end of 2027.
Report  Overview: https://www.transparencymarketresearch.com/tamiflu-oseltamivir-
phosphate-market.html 
Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing 
their production capabilities to manufacture novel medication for the 
prevention and treatment of life-threatening influenza diseases and other 
flu. They are increasing efficacy in FDA negotiations for marketing and 
scientific engagement associated with Tamiflu to gain credibility in the 
global market landscape.
To know the scope of our report Get a Sample on Tamiflu 
(Oseltamivir Phosphate) Market
Popularity of OTC Distribution in U.S. Catches Attention of Leading
Healthcare Companies
The Tamiflu (Oseltamivir Phosphate) market is witnessing change, since 
healthcare companies are pervasively switching toward OTC distribution, 
especially in the U.S. Since the U.S. being one of the rapidly growing 
economies of North America, the latter is expected to reach the second-
highest revenue in the Tamiflu (Oseltamivir Phosphate) market by the end
of 2027. Hence, companies in the U.S. are capitalizing on the trend of 
OTC switch. Looking at leading market players, even emerging players are
aiming at the OTC switch and aiming toward strategic transactions to 
introduce innovations in Tamiflu (Oseltamivir Phosphate).
Companies in the market for Tamiflu (Oseltamivir Phosphate) are 
targeting the U.S., since the region is one of the largest OTC market 
worldwide. The OTC switch is supporting the global cough and cold 
strategy of market players by expanding into flu with a sustainable point 
of difference in the market. Tamiflu is being highly publicized in support of
public health, since novel medication offers safe and efficacious treatment
for flu and influenza.
Companies Target Patients with Renal Diseases to Grow in Global 
Market
Health institutions such as the Centers for Disease Control and Prevention,
U.S., recommend that newly born infants should receive flu vaccine at 
regular periodic intervals. However, frequent replication and mutation of 
the influenza virus has contributed toward high prevalence of the 
infection. This phenomena has fueled the demand for Tamiflu (Oseltamivir
Phosphate) medication. However, substitute antiviral drugs such as 
Baloxavir marboxil and Peramivir pose as a threat to the sales of Tamiflu 
(Oseltamivir Phosphate). Easy availability of substitute drugs explains the 
steep downward Y-o-Y growth of the Tamiflu (Oseltamivir Phosphate) 
market. Hence, manufacturers are entering into strategic deals for OTC 
distribution and increasing production capabilities in dosage forms of 
Tamiflu.
Get a glimpse of the in-depth analysis through our Report Brochure
Tamiflu capsules dictate the highest revenue as compared to suspension 
dosages in the Tamiflu (Oseltamivir Phosphate) market and the capsule 
dosage form segment is predicted for exponential growth in the coming 
years. On the other hand, companies are increasing the availability of 
Tamiflu in the suspension dosage form for patients with end-stage renal 
disease (ESRD) and those on continuous ambulatory peritoneal 
dialysis (CAPD).
Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?
flag=S&rep_id=70965 
Publicly Funded Research Studies in Europe Offer Strategic 
Insights to Healthcare Companies
It has been found that Tamiflu (Oseltamivir Phosphate) is an efficacious 
antiviral drug for the treatment of flu and influenza, especially among the 
geriatric patients. Companies in the Tamiflu (Oseltamivir Phosphate) 
market are increasing their focus in Europe, this market in the region is 
expected for aggressive growth during the forecast period. The Lancet- a 
European Commission-funded study revealed that Tamiflu (Oseltamivir 
Phosphate) is recommended by public health agencies for the prevention 
and treatment of seasonal and pandemic influenza outbreaks.
Ongoing research studies that are publicly funded in several European 
countries are generating incremental opportunities for companies in the 
Tamiflu (Oseltamivir Phosphate) market, since companies are gaining 
important insights through these studies. Healthcare providers in Europe 
are also recommending Tamiflu for young and old patients with flu-like 
illnesses.
Expanding operations in future? To get the perfect launch ask for a 
custom report 
Analysts’ Viewpoint
Healthcare companies in the Tamiflu (Oseltamivir Phosphate) market are 
exploring opportunities in Asia Pacific, since government institutions in 
the region are increasing their efforts to improve the healthcare 
infrastructure. On the other hand, companies are maximizing their 
production capabilities to develop generic drugs and increasing efforts to 
strengthen their online distribution channels.
Tamiflu is efficacious in the treatment of ESRD and for patients who rely 
on CAPD. However, side effects of Tamiflu, such as diarrhea, and 
introduction of substitute drugs such as XofluzaTM (baloxavir 
marboxil) by Roche, are likely to slow down market growth. Hence, 
companies should increase their efficacy in conducting extensive research
studies catering to the development of drugs targeting children and 
infants.
Tamiflu (Oseltamivir Phosphate) Market: Overview
 Tamiflu (Oseltamivir Phosphate) is a medicine under the class of 
neuraminidase inhibitor used as an antiviral agent
 This drug is widely used for the treatment of symptoms caused by the flu 
virus (Influenza). Tamiflu is a brand name, while oseltamivir phosphate is a
generic name for the same. It is available in capsule and oral suspension 
dosage forms.
 Seasonal outbreak of influenza primarily occurs in winter. Most people 
generally recover fully, but severe complications such as pneumonia can 
also develop. Initiation of antiviral treatment is recommended for 
hospitalized influenza patients.
 Tamiflu is prescribed for the treatment of acute, and uncomplicated 
influenza A and B in patients 2 weeks of age and older who have been 
symptomatic for no more than 48 hours. It is also given for prophylactic 
use as prophylaxis of influenza A and B in patients 1 year and older.
 Prevention of flu includes avoiding unnecessary close contact between 
sick and healthy people, covering mouth and nose while coughing & 
sneezing, and washing hands frequently
 High prevalence, rise in patient population affected by influenza, and 
pandemic influenza outbreak are some of the major factors responsible for
the growth of global Tamiflu (Oseltamivir Phosphate) market
 For instance, according to the Centers for Disease Control and Prevention 
(CDC), around 5% to 20% of the population is affected by the flu in the 
U.S. each year. Additionally, an estimated 200,000 people are hospitalized
due to flu infection in the U.S. each year; of these 36,000 die due to flu 
complications.
 Increase in initiatives by regulatory authorities & organizations for 
treatment and prevention of influenza is also contributing for the growth 
of the global Tamiflu (Oseltamivir Phosphate) market
 Moreover, surge in government funding and measures for influenza 
treatment & prevention in terms of research activities and awareness 
campaigns is responsible for the growth of Tamiflu (Oseltamivir 
Phosphate) market
EnquiryBeforeBuying: 
https://www.transparencymarketresearch.com/sample/sample.php?
flag=EB&rep_id=70965 
Market Segmentation: Tamiflu (Oseltamivir Phosphate) Market
 Based on drug type, the global Tamiflu (Oseltamivir Phosphate) market 
has been classified into branded and generic
 The generic segment dominated the global Tamiflu (Oseltamivir 
Phosphate) market in 2018 and its share in global market in increasing
 Patent expiry of branded Tamiflu in 2016, several generic products 
launches, and cheaper products are some of the major factors driving the 
generic segment
 In terms of dosage form, the global Tamiflu (Oseltamivir Phosphate) 
market has been bifurcated into capsule and suspension
 On the basis of Indication, the global market has been segmented into 
influenza A, influenza B, and others
 Based on distribution channel, the global Tamiflu (Oseltamivir Phosphate) 
market has been divided into hospital pharmacies, retail pharmacies, 
online pharmacies, and others
 Each of the segments has been analyzed in detail for market trends, 
recent trends and developments, drivers, restraints, opportunities, and 
useful insights
 The report provides current and future revenue (US$ Mn) for each of these
segments for the period from 2017 to 2027, considering 2018 as the 
base year. The compound annual growth rate (% CAGR) has been 
provided for each segment and market from 2019 to 2027, along with 
market size estimations.
Regional Overview: Tamiflu (Oseltamivir Phosphate) Market
 In terms of region, the global Tamiflu (Oseltamivir Phosphate) market has 
been divided into North America, Europe, Asia Pacific, Latin America, and 
Middle East & Africa. The regions have been further divided into major 
countries and sub-regions.
 North America accounted for major share of the global Tamiflu 
(Oseltamivir Phosphate) market in 2018. Higher prevalence of influenza, 
presence of major companies in the region, and better influenza 
surveillance for reporting on weekly basis are some of the major factors 
responsible for the growth of North America Tamiflu (Oseltamivir 
Phosphate) market.
 The current and future market sizes in terms of revenue (US$ Mn) of these
regional markets and their major countries have been provided in the 
report for the period from 2017 to 2027, with their CAGRs for the period 
from 2019 to 2027
 The study also offers a list of recommendations, highlights, and useful 
insights of the market, which will help new companies willing to enter the 
market and existing companies to increase market shares, and help in the 
decision-making process
Major Players
 The report concludes with company profiles section that includes key 
information about the major players in the market
 Key players analyzed in this report are
o F.Hoffmann-La Roche Ltd.
o NATCO Pharma Limited
o Tea Pharmaceutical Industries Ltd.
o LUPIN Limited
o Amneal Pharmaceuticals LLC
o Zydus Cadila
o Sun Pharmaceutical Industries Ltd.
o Alembic Pharmaceuticals Limited
o Mylan N.V.
About Transparency Market Research
Transparency Market Research registered at Wilmington, 
Delaware, United States, is a global market research company 
providing custom research and consulting services. TMR 
provides in-depth insights into factors governing demand in the
market. It divulges opportunities across various segments 
based on Source, Application, Sales Channel, and End-Use that 
will favor growth in the market over the next 9 years.
Our data repository is continuously updated and revised by a 
team of research experts, so that it always reflects the latest 
trends and information. With a broad research and analysis 
capability, Transparency Market Research employs rigorous 
primary and secondary research techniques in developing 
distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit 
Our YouTube Channel and hit subscribe for Future 
Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]